Given that the expression of TGF-β1 and -β2 strongly correlates to poor survival in patients with glioblastoma (73) and the notion that our engineered bifunctional FC5-Fc-fusions neutralize TGF-β1 and TGF-β2 (albeit to a lesser extent) underscores the therapeutic potential of these molecules. This evidence concerns the gene TGFB2 and glioblastoma.